IN2014CN02515A - - Google Patents

Info

Publication number
IN2014CN02515A
IN2014CN02515A IN2515CHN2014A IN2014CN02515A IN 2014CN02515 A IN2014CN02515 A IN 2014CN02515A IN 2515CHN2014 A IN2515CHN2014 A IN 2515CHN2014A IN 2014CN02515 A IN2014CN02515 A IN 2014CN02515A
Authority
IN
India
Prior art keywords
directed
present
diseases
involved
prevention
Prior art date
Application number
Other languages
English (en)
Inventor
Scott D Kuduk
Jason W Skudlarek
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN02515A publication Critical patent/IN2014CN02515A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2515CHN2014 2011-10-19 2012-10-17 IN2014CN02515A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548883P 2011-10-19 2011-10-19
PCT/US2012/060479 WO2013059222A1 (fr) 2011-10-19 2012-10-17 Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-4-nitrile

Publications (1)

Publication Number Publication Date
IN2014CN02515A true IN2014CN02515A (fr) 2015-07-31

Family

ID=47116466

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2515CHN2014 IN2014CN02515A (fr) 2011-10-19 2012-10-17

Country Status (11)

Country Link
US (1) US9156819B2 (fr)
EP (1) EP2768823B1 (fr)
JP (1) JP5947906B2 (fr)
CN (1) CN103874695B (fr)
AR (1) AR088352A1 (fr)
AU (1) AU2012326275B2 (fr)
BR (1) BR112014009486A2 (fr)
CA (1) CA2852425C (fr)
IN (1) IN2014CN02515A (fr)
TW (1) TW201317228A (fr)
WO (1) WO2013059222A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009281A (es) 2012-02-07 2015-01-12 Eolas Therapeutics Inc Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina.
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
EP2908812A4 (fr) * 2012-10-16 2016-04-20 Merck Sharp & Dohme Antagonistes de type 2-pyridyloxy-3-ester-4-nitrile des récepteurs d'orexines
WO2014066196A1 (fr) * 2012-10-23 2014-05-01 Merck Sharp & Dohme Corp. Antagonistes du récepteur de la 2-pyridyloxy-3-substituée-4-nitrile oréxine
US9624197B2 (en) * 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2934516A4 (fr) * 2012-12-20 2016-07-20 Merck Sharp & Dohme Antagonistes des récepteurs de l'orexine 3-ester-4-substitués
WO2014099698A1 (fr) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-3-nitrile substitué en 4
US9556145B2 (en) * 2012-12-20 2017-01-31 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ester orexin receptor antagonists
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
US9725434B2 (en) * 2013-04-23 2017-08-08 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
WO2015018029A1 (fr) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Composés oxazole antagonistes des récepteurs d'orexine
WO2015018027A1 (fr) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Antagonistes thiazoles des récepteurs de l'orexine
US9586934B2 (en) 2013-12-09 2017-03-07 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
US9975876B2 (en) 2013-12-09 2018-05-22 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
WO2015095108A1 (fr) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Composés thioéther-pipéridinyle servant d'antagonistes des récepteurs de l'orexine
WO2015095441A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés 2-amino-3-ester-pyridyle servant d'antagonistes des récepteurs de l'orexine
WO2015131773A1 (fr) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 Dérivés de pipéridine utilisés comme antagonistes du récepteur de l'orexine
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
BR112017004742B1 (pt) 2014-09-11 2022-11-29 Janssen Pharmaceutica Nv 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina
WO2016065586A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole et tétrazole antagonistes des récepteurs de l'orexine
WO2016065585A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Composés pipéridines isoxazoles et isothiazoles antagonistes des récepteurs de l'orexine
WO2016065584A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Antagonistes pipéridine oxadiazole et pipéridine thiadiazole du récepteur de l'orexine
WO2016065583A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Antagonistes du récepteur d'orexine à base d'oxazole
WO2016065587A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Composés pyrazoles antagonistes des récepteurs de l'orexine
WO2016083315A1 (fr) * 2014-11-24 2016-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires
US10000499B2 (en) 2014-11-26 2018-06-19 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
WO2016085783A1 (fr) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Composés de diazépane pontés utiles en tant qu'antagonistes des récepteurs d'orexine
WO2016086357A1 (fr) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Méthyl oxazoles antagonistes du récepteur d'orexine
WO2016086358A1 (fr) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxyméthyl pipéridines antagonistes du récepteur d'orexine
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016095204A1 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Composés pyrrolidine en tant qu'antagonistes du récepteur de l'hypocrétine
US9987255B2 (en) 2014-12-19 2018-06-05 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
WO2016095205A1 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Composés hétéroaryle en tant qu'antagonistes du récepteur de l'hypocrétine
US10011595B2 (en) 2014-12-19 2018-07-03 Merck Sharp & Dohme Corp. Ethyldiamine orexin receptor antagonists
WO2016101119A1 (fr) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Dérivés d'hétéroaryles fusionnés en tant qu'antagonistes des récepteurs des oréxines
WO2016101118A1 (fr) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Antagonistes des récepteurs d'orexine de type amidoéthylazole
CA3005918C (fr) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Derives d'octahydropyrrolo [3, 4-c] pyrrole et leurs utilisations
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
EP3454857A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
SG11202000831XA (en) 2017-08-03 2020-02-27 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
CA1258454A (fr) 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
IT1159765B (it) 1982-09-28 1987-03-04 Zanussi A Spa Industrie Macchina lavabiancheria di tipo modulare
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
WO1990005525A1 (fr) 1988-11-23 1990-05-31 Pfizer Inc. Derives de quinuclidine en tant qu'antagonsites de substance p
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
DE69220258T2 (de) 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
EP0573522B1 (fr) 1991-03-01 1994-12-14 Pfizer Inc. Derives de 1-azabicyclo[3.2.2]nonan-3-amine
ATE136885T1 (de) 1991-08-20 1996-05-15 Merck Sharp & Dohme Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GB9211193D0 (en) 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5496833A (en) 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
CA2203878C (fr) 1994-11-07 2002-06-25 John M. Peterson Certains derives de benzylamine a substitutions; une nouvelle classe de ligands specifiques du neuropeptide y1
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997020821A1 (fr) 1995-12-01 1997-06-12 Novartis Ag Derives heteroaryles
WO1997020823A2 (fr) 1995-12-01 1997-06-12 Novartis Ag Antagonistes de recepteurs
WO1997020822A1 (fr) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines en tant qu'antagoniste du recepteur du neuropeptide y
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP0887340A4 (fr) 1996-02-06 2000-03-29 Japan Tobacco Inc Composes chimiques et utilisation pharmaceutique
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP0955293B1 (fr) 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Derives d'uree
DE69719544T2 (de) 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
CA2274593A1 (fr) 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyrazole
AU7738198A (en) 1996-12-15 1998-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
DE69822449T2 (de) 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
JP2001511147A (ja) 1997-02-04 2001-08-07 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・アーカンソー 殺菌・殺カビ性のカルボキサミド類
TR199902012T2 (xx) 1997-02-21 2000-01-21 Bayer Aktiengesellschaft Arils�lfonamidler ve analoglar�
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
CA2283797A1 (fr) 1997-03-18 1998-09-24 Paul Elliot Bender Nouveaux agonistes de recepteurs de cannabinoides
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6258837B1 (en) 1997-04-23 2001-07-10 Banyu Pharmaceutical Co., Ltd. Neuropeptide Y receptor antagonist
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
AU9185598A (en) 1997-09-25 1999-04-12 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
AU1262199A (en) 1997-11-28 1999-06-16 Banyu Pharmaceutical Co., Ltd. Antihyperlipemic agents
JP2002510688A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換９Ｈ−ピリジノ［２，３−ｂ］インドールおよび９Ｈ−ピリミジノ［４，５−ｂ］インドール誘導体
WO1999055667A1 (fr) 1998-04-29 1999-11-04 Ortho-Mcneil Pharmaceutical, Inc. Aminotetralines n substituees, ligands du recepteur y y5 du neuropeptide servant au traitement de l'obesite et d'autres troubles
CA2331735A1 (fr) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Derives de phenyluree et de (phenylthio)uree
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
EP1129089B1 (fr) 1998-11-10 2005-12-28 Merck & Co., Inc. Spiro-indolines en tant qu'antagonistes du recepteur y5
DE60015927T2 (de) 1999-02-12 2005-04-07 Smithkline Beecham P.L.C., Brentford Phenylharnstoff und phenylthioharnstoffderivate
WO2000047576A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2000047577A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
WO2000064880A1 (fr) 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Antagonistes selectifs npy (y5)
WO2000068197A1 (fr) 1999-05-05 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. LIGANDS DE RECEPTEURS DU NEUROPEPTIDE Y DERIVES DE 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE, UTILISES POUR LE TRAITEMENT DE L'OBESITE ET D'AUTRES ETATS PATHOLOGIQUES
DE60023128T2 (de) 1999-05-12 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE306477T1 (de) 1999-06-30 2005-10-15 Lundbeck & Co As H Selektive npy (y5) antagonisten
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE60023148T2 (de) 1999-07-28 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
US6462053B1 (en) 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
CA2386474A1 (fr) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001023387A2 (fr) 1999-09-30 2001-04-05 Neurogen Corporation PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
KR20020043223A (ko) 1999-09-30 2002-06-08 해피 페너 ; 해리 에이치. 페너 2세 알킬렌 디아민 치환 헤테로사이클 화합물
CN1377355A (zh) 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
AU2261401A (en) 1999-12-16 2001-06-25 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
RU2259365C2 (ru) 2000-01-20 2005-08-27 Эйсай Ко., Лтд. Пиперидиновое соединение, способ его получения, фармацевтическая композиция и способ ингибирования натриевых каналов и калиевых каналов
WO2001056592A1 (fr) 2000-02-01 2001-08-09 Novo Nordisk A/S Utilisation de composes pour la regulation de l'absorption de nourriture
WO2001058869A2 (fr) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
CA2400659A1 (fr) 2000-02-22 2001-08-30 Banyu Pharmaceutical Co., Ltd. Composes a base d'imidazoline
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
AU2001260113B2 (en) 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
EP1142886A1 (fr) 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Percyquinine, procédé pour sa production et son utilisation comme produit pharmaceutique
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
US6479482B2 (en) 2000-05-10 2002-11-12 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine NPY antagonists
CA2408486A1 (fr) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance
AU779266B2 (en) 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
CA2408913A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2001087335A2 (fr) 2000-05-17 2001-11-22 Eli Lilly And Company Procede d'inhibition selective de la ghreline
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
PT1289955E (pt) 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
JP2004504406A (ja) 2000-07-24 2004-02-12 アーダナ　バイオサイエンス　リミテッド グレリンアンタゴニスト
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
JP2004509108A (ja) 2000-09-14 2004-03-25 シェーリング　コーポレイション 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト
DE60104141T2 (de) 2000-10-13 2005-06-30 Eli Lilly And Co., Indianapolis Substituierte dipeptide zur förderung der sekretion von wachstumshormon
CA2422698C (fr) 2000-10-16 2009-12-15 F. Hoffmann-La Roche Ag Derives d'indoline et leur utilisation en tant que ligands de recepteur 5-ht2
WO2002036596A2 (fr) 2000-11-03 2002-05-10 Wyeth Cycloalkyl[b][1,4]diazepino[6,7,1-hi]indoles et derives
CA2428905A1 (fr) 2000-11-20 2002-05-23 Biovitrum Ab Composes de piperazinylpyrazines utilises comme antagonistesdu recepteur de la serotonine 5-ht2
DE60142355D1 (de) 2000-11-20 2010-07-22 Biovitrum Ab Publ Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
BR0116113A (pt) 2000-12-12 2004-08-03 Neurogen Corp Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432809C (fr) 2000-12-21 2010-11-30 Schering Corporation Antagonistes du recepteur de neuropeptide y y5 d'uree heteroaryle
ES2243588T3 (es) 2000-12-22 2005-12-01 Schering Corporation Antagonistas piperidinicos de la mch y su uso en el tratamientyo de la obesidad.
JP4094950B2 (ja) 2000-12-27 2008-06-04 エフ．ホフマン−ラ ロシュ アーゲー インドール誘導体および５−ｈｔ２ｂおよび５−ｈｔ２ｃ受容体リガンドとしてのそれらの使用
WO2002051232A2 (fr) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes
WO2002062764A1 (fr) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Composes heterocycliques condenses
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
US7034056B2 (en) 2001-03-21 2006-04-25 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
UA74066C2 (en) 2001-03-22 2005-10-17 Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR035234A1 (es) 2001-04-12 2004-05-05 Pharmacopeia Drug Discovery Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento
ATE383359T1 (de) 2001-05-05 2008-01-15 Smithkline Beecham Plc N-aroyl zyklische amine
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6953801B2 (en) 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
ATE318139T1 (de) 2001-06-20 2006-03-15 Merck & Co Inc Dipeptidylpeptidase-hemmer zur behandlung von diabetes
EP1406872B1 (fr) 2001-06-20 2007-12-19 Merck & Co., Inc. Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
WO2003002593A2 (fr) 2001-06-27 2003-01-09 Probiodrug Ag Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
WO2003002530A2 (fr) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
BR0210644A (pt) 2001-06-27 2004-07-20 Smithkline Beecham Corp Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
HUP0400326A2 (hu) 2001-06-28 2004-09-28 Smithkline Beecham P.L.C. Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
JP2005502624A (ja) 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
EP1411942A4 (fr) 2001-07-05 2005-01-26 Synaptic Pharma Corp Piperidines aniliniques substituees, utilisees comme antagonistes selectifs de la mch
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
BRPI0104510B8 (pt) 2001-07-27 2021-05-25 Embrapa Pesquisa Agropecuaria peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada
AU2002323787B2 (en) 2001-08-07 2008-04-24 Banyu Pharmaceutical Co., Ltd. Spiro compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP2005320249A (ja) 2002-05-01 2005-11-17 Banyu Pharmaceut Co Ltd ２−アミノピラジン誘導体の製造方法
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7067519B2 (en) 2002-07-09 2006-06-27 Hamed Aissaoui 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
WO2004026866A1 (fr) 2002-09-18 2004-04-01 Glaxo Group Limited Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine
US6869966B2 (en) 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
AU2003273697A1 (en) 2002-10-08 2004-05-04 Merck Frosst Canada Ltd 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
EP1554239B1 (fr) 2002-10-11 2011-01-26 Actelion Pharmaceuticals Ltd. Derives d'acide sulfonylamino-acetique
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
US6951882B2 (en) 2002-12-12 2005-10-04 Janssen Pharmaceutica N.V. Substituted 4-phenyl-[1,3]-dioxanes
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
KR20050114242A (ko) 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
JP2007523846A (ja) 2003-04-28 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド キノキサリノン誘導体
RU2006100298A (ru) 2003-06-11 2006-05-10 Мерк энд Ко., Инк. (US) Замещенные производные 3-алкил-и 3-алкенилазетидинов
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
WO2005118548A1 (fr) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tétrahydroisoquinoléine substitués
WO2006067224A2 (fr) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Nouveaux composes
DE102004062544A1 (de) 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
EP1871752A4 (fr) 2005-04-12 2009-09-30 Merck & Co Inc Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
EP1871762A2 (fr) * 2005-04-18 2008-01-02 Neurogen Corporation Antagonistes cb1 heteroaryle substitue
WO2006117669A1 (fr) 2005-05-03 2006-11-09 Pfizer Inc. Composes d'amide resorcinol
US20090118200A1 (en) 2005-05-23 2009-05-07 Bergman Jeffrey M Proline bis-amide orexin receptor antagonists
CA2617324A1 (fr) 2005-08-04 2007-02-15 Merck & Co., Inc. Antagonistes des recepteurs d'orexine a base de sulfamide d'aminoethane
CA2620124A1 (fr) 2005-08-26 2007-03-01 Merck And Co., Inc. Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
EP1954276A2 (fr) 2005-11-22 2008-08-13 Merck & Co., Inc. Antagonistes des recepteurs de l'indole orexine
CA2647678A1 (fr) 2006-03-29 2007-11-08 Merck & Co., Inc. Antagonistes des recepteurs de l'orexine sous forme de composes diazepane
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
WO2007116374A1 (fr) 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Nouveaux composés sulfonamides
DE602007012072D1 (de) 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd Orantagonisten
US20090192143A1 (en) 2006-07-14 2009-07-30 Cox Christopher D Substituted diazepan orexin receptor antagonists
JP2009543790A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド ２−置換プロリンビス−アミドオレキシン受容体アンタゴニスト
EP2049110B1 (fr) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
CN101506199A (zh) 2006-08-15 2009-08-12 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的氮杂环丁烷化合物
EP2059520B1 (fr) 2006-08-28 2010-02-24 Actelion Pharmaceuticals Ltd. Dérivés de 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulène en tant qu'antagonistes de récepteur d'orexine
KR20090077051A (ko) 2006-09-29 2009-07-14 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.1.0]헥산 유도체
JP2010511038A (ja) * 2006-12-01 2010-04-08 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体阻害剤としての３−ヘテロアリール（アミノ又はアミド）−１−（ビフェニル又はフェニルチアゾリル）カルボニルピペリジン誘導体
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US8410142B2 (en) * 2007-03-02 2013-04-02 Merck Sharp & Dohme Corp. Bipyridine carboxamide orexin receptor antagonists
MY148544A (en) 2007-05-23 2013-04-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
AU2008284268A1 (en) * 2007-08-09 2009-02-12 Merck & Co., Inc. Pyridine carboxamide orexin receptor antagonists
CN101903372B (zh) * 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN102015645B (zh) * 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
US8674093B2 (en) 2008-05-22 2014-03-18 Merck Canada Inc. Process for the preparation of an orexin receptor antagonist
JP2012506374A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2350061B1 (fr) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. Antagonistes de récepteur de l'orexine de type pipéridine 2,3-disubstituée
CA2739917A1 (fr) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Antagonistes de recepteur d'orexine de morpholine 2,5-disubstituee
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506377A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，４−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
AU2009307921A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
JP5635991B2 (ja) * 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
EP2349262B1 (fr) * 2008-10-30 2014-06-25 Merck Sharp & Dohme Corp. Antagonistes carboxamide phényl 2,5-disubstitué du récepteur de l orexine
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
WO2011023578A1 (fr) * 2009-08-24 2011-03-03 Glaxo Group Limited Dérivés de 5-méthylpipéridine comme antagonistes de récepteurs à orexines pour le traitement d'un trouble du sommeil
WO2014066196A1 (fr) * 2012-10-23 2014-05-01 Merck Sharp & Dohme Corp. Antagonistes du récepteur de la 2-pyridyloxy-3-substituée-4-nitrile oréxine

Also Published As

Publication number Publication date
AU2012326275A1 (en) 2014-04-17
EP2768823B1 (fr) 2017-09-06
US20130102619A1 (en) 2013-04-25
CA2852425C (fr) 2019-11-12
BR112014009486A2 (pt) 2017-05-09
AR088352A1 (es) 2014-05-28
TW201317228A (zh) 2013-05-01
CN103874695B (zh) 2017-12-15
WO2013059222A1 (fr) 2013-04-25
CA2852425A1 (fr) 2013-04-25
EP2768823A1 (fr) 2014-08-27
US9156819B2 (en) 2015-10-13
JP2014532624A (ja) 2014-12-08
AU2012326275B2 (en) 2016-12-01
JP5947906B2 (ja) 2016-07-06
CN103874695A (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
IN2014CN02515A (fr)
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
WO2016100157A3 (fr) Antagonistes octahydropyrrolopyridines 6,5-bicycliques du récepteur d'orexine
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
WO2016100162A3 (fr) Antagonistes oxazoles 5,5-bicycliques du récepteur d'orexine
WO2016106106A3 (fr) Dérivés d'hétéroaryle fusionnés utilisés comme antagonistes de récepteurs de l'orexine
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
GEP20156285B (en) Compounds and compositions as trk inhibitors
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
MX2017006048A (es) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetrahidropiridi nas en calidad de inhibidores de bace1 para tratar enfermedad de alzheimer.
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
NZ707832A (en) 2-pyridone compound
IN2014KN00849A (fr)
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
TN2013000179A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists